BMY Beats on Q3 Earnings and Sales, Raises 2025 Sales View

Key Takeaways Bristol-Myers posted Q3 EPS of $1.63 and revenues of $12.2B, topping consensus estimates.Growth Portfolio sales climbed 18% to $6.8B, led by Opdivo, Reblozyl, Breyanzi and Camzyos.Legacy drugs declined but Eliquis surged 25%. Bristol-Myers Squibb Company (BMY) reported third-quarter 2025 adjusted earnings per share (EPS) of $1.63, which comfortably beat the Zacks Consensus Estimate of $1.48. In the year-ago quarter, BMY posted adjusted earnings per share of $1.80.Total revenues of $12.2 billio ...